Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether rasagiline is effective in the treatment of
Progressive Supranuclear Palsy (PSP), a rapidly progressing disease with a symptomatology
similar to Parkinson's Disease. The major aim of this study is the limitation or halting of
the process of neurodegeneration and influence postural instability.
Phase:
Phase 3
Details
Lead Sponsor:
Prof. Dr. Stefan Lorenzl
Collaborators:
Ludwig-Maximilians - University of Munich Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries